C12N 2760/16032
Use of virus as therapeutic agent, other than vaccine
Official title: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N2760/16032 (Use of virus as therapeutic agent, other than vaccine) appears on 7 US grants and 12 published applications in this corpus.
Search patents in C12N- Granted patents
- 7
- Published applications
- 12
- Assignees
- 3
- Inventors
- 11
- Latest grant
- 10 Sep 2019
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2006 | 0 | 1 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 1 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 2 |
| 2012 | 0 | 0 |
| 2013 | 0 | 1 |
| 2014 | 1 | 0 |
| 2015 | 1 | 1 |
| 2016 | 0 | 2 |
| 2017 | 2 | 1 |
| 2018 | 1 | 1 |
| 2019 | 1 | 0 |
| 2020 | 0 | 2 |
| 2021 | 0 | 0 |
| 2022 | 0 | 0 |
| 2023 | 0 | 1 |
By publication year.
Recent patents
- Recombinant vectors10 Sep 2019US 10,407,666 B2Tocagen Inc.
- Tissue targeted antigenic activation of the immune response to treat cancers2 Oct 2018US 10,086,066 B2Qu Biologics Inc.
- Tissue targeted antigenic activation of the immune response to treat cancers3 Oct 2017US 9,775,896 B2Qu Biologics Inc.
- Recombinant vectors15 Aug 2017US 9,732,326 B2Tocagen Inc.
- Tissue targeted antigenic activation of the immune response to treat cancers18 Aug 2015US 9,107,864 B2Qu Biologics Inc.
- Destroying Cancer Cells While Maintaining Healthy Cell Integrity30 Nov 2023US 2023/0381294 A1
- Recombinant vectors30 Jul 2020US 2020/0239858 A1Tocagen Inc.
- Tissue Targeted Antigenic Activation of the Immune Response to Treat Cancers23 Apr 2020US 2020/0121784 A1Qu Biologics Inc.
- Recombinant vectors29 Mar 2018US 2018/0087035 A1Tocagen Inc.
- Tissue Targeted Antigenic Activation of the Immune Response to Treat Cancers28 Dec 2017US 2017/0368166 A1Qu Biologics Inc.
Most cited
By later US patents
- Tissue targeted antigenic activation of the immune response to treat cancers13US 9,107,864 B2Qu Biologics Inc. · 2015
- Recombinant vectors5US 8,829,173 B2Tocagen Inc. · 2014
- Tissue targeted antigenic activation of the immune response to treat cancers5US 9,775,896 B2Qu Biologics Inc. · 2017
- Recombinant vectors3US 9,732,326 B2Tocagen Inc. · 2017
- Tissue targeted antigenic activation of the immune response to treat cancers2US 10,086,066 B2Qu Biologics Inc. · 2018